As of May 2024 Novavax has a market cap of $2.12 Billion. This makes Novavax the world's 4064th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2024 | $2.12 B | 272% |
2023 | $0.57 B | -34.75% |
2022 | $0.87 B | -91.92% |
2021 | $10.81 B | 52.38% |
2020 | $7.09 B | 5413.03% |
2019 | $0.12 B | -81.8% |
2018 | $0.70 B | 51.97% |
2017 | $0.46 B | 36.2% |
2016 | $0.34 B | -84.91% |
2015 | $2.26 B | 59.93% |
2014 | $1.41 B | 32.57% |
2013 | $1.06 B | 282.07% |
2012 | $0.27 B | 93.02% |
2011 | $0.14 B | -46.31% |
2010 | $0.26 B | 1.17% |
2009 | $0.26 B | 104.01% |
2008 | $0.13 B | -36.63% |
2007 | $0.20 B | -18.57% |
2006 | $0.25 B | 20.22% |
2005 | $0.21 B | 63.42% |
2004 | $0.12 B | -38.1% |
2003 | $0.20 B | 220.84% |
2002 | $64.92 M | -80.23% |
2001 | $0.32 B |
On May 15th, 2024 the market cap of Novavax was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
Novartis NVS | $209.52 B | 9,778.39% | ๐จ๐ญ Switzerland |
Pfizer PFE | $163.87 B | 7,626.11% | ๐บ๐ธ USA |
AstraZeneca AZN | $238.86 B | 11,161.19% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $92.54 B | 4,262.99% | ๐ฌ๐ง UK |
Sarepta Therapeutics
SRPT | $12.54 B | 491.54% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | $2.63 B | 24.11% | ๐บ๐ธ USA |
Agenus
AGEN | $0.22 B | -89.60% | ๐บ๐ธ USA |
NanoViricides NNVC | $26.26 M | -98.76% | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | $1.33 B | -37.05% | ๐บ๐ธ USA |
Emergent BioSolutions
EBS | $0.27 B | -86.98% | ๐บ๐ธ USA |